Co-founder of WestChina-Frontier PharmaTech. 30 years' experience in drug safety and efficacy study management, PK/PD study and drug safety evaluation. 10 years' research and work experience in Japan academia. NMPA New Drug Reviewer. Ministry of Health of China Cosmetic Reviewer.

Co-founder of WestChina-Frontier PharmaTech. GLP regulation expert. 16 years' experience in drug safety and efficacy study management.

Research and work experience in Japan academia. NMPA New Drug Reviewer. NMPA New Drug Review Committee External Consultant.

Joined WestChina-Frontier PharmaTech early after its inception. GLP regulation expert. Laboratory animal regulation expert.

Over 30 years' experience in toxicology study management. Research and working experience in North America academia. AAALAC International Inspector. NMPA New Drug Reviewer.

Dr. Hui Zhang has worked in pharmaceutical companies such as AstraZeneca and NovoNordisk for 20 Years.

She is a member of the Society of Toxicology pathology (STP), Society of European Toxicology Pathology (ESTP), Association of Inhalation Toxicology (AIT). She is a committee member of INHAND（International Harmonization of Nomenclature and Diagnostic Criteria） Special Sensory Working Group. Dr. Zhang is the CSO of WCFP as well as the director of pharmacology department.